Literature DB >> 11744754

Role of tyrosine kinase activity in alpha-adrenergic inhibition of the beta-adrenergically regulated L-type Ca(2+) current in guinea-pig ventricular myocytes.

A E Belevych1, A Nulton-Persson, C Sims, R D Harvey.   

Abstract

1. The purpose of this study was to investigate the hypothesis that tyrosine kinase activity contributes to alpha(1)-adrenergic inhibition of beta-adrenergic responses in cardiac myocytes. We addressed this question by studying the pharmacological regulation of the L-type Ca(2+) current in acutely isolated adult guinea-pig ventricular myocytes using the whole-cell patch-clamp technique. 2. The selective alpha(1)-adrenergic receptor agonist methoxamine had no effect on the basal L-type Ca(2+) current. Methoxamine also had no effect on cAMP-dependent stimulation of the Ca(2+) current mediated by H(2) histamine receptor activation. However, methoxamine did inhibit cAMP-dependent stimulation of the Ca(2+) current mediated by beta-adrenergic receptor activation. The ability of methoxamine to inhibit beta-adrenergic regulation of the Ca(2+) current was significantly antagonized by the tyrosine kinase inhibitors genistein and lavendustin A. 3. The inhibitory effect of methoxamine was also mimicked by the phosphotyrosine phosphatase inhibitor pervanadate (PVN). PVN had no effect on basal Ca(2+) current or Ca(2+) current stimulated by histamine, but it did inhibit Ca(2+) current stimulated by beta-adrenergic receptor activation. Furthermore, the ability of PVN to inhibit beta-adrenergic stimulation of the Ca(2+) current was antagonized by lavendustin A. 4. These results are consistent with the conclusion that in guinea-pig ventricular myocytes alpha-adrenergic inhibition of beta-adrenergic responses involves a tyrosine kinase-dependent signalling pathway. The fact that methoxamine and PVN antagonized cAMP-dependent responses mediated by beta-adrenergic, but not H(2) histamine, receptor activation suggests that the inhibitory effect of alpha-adrenergic stimulation and tyrosine kinase activity is at the level of the beta-adrenergic receptor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11744754      PMCID: PMC2278981          DOI: 10.1111/j.1469-7793.2001.00779.x

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  31 in total

1.  Tyrosine phosphatase inhibitors selectively antagonize beta-adrenergic receptor-dependent regulation of cardiac ion channels.

Authors:  C Sims; J Chiu; R D Harvey
Journal:  Mol Pharmacol       Date:  2000-12       Impact factor: 4.436

2.  Use and specificity of genistein as inhibitor of protein-tyrosine kinases.

Authors:  T Akiyama; H Ogawara
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

3.  On the mechanism of histamine induced enhancement of the cardiac Ca2+ current.

Authors:  J Hescheler; M Tang; B Jastorff; W Trautwein
Journal:  Pflugers Arch       Date:  1987-09       Impact factor: 3.657

4.  Alpha 1-adrenoceptor stimulation reduced the positive chronotropic effect of simultaneously administered beta-adrenoceptor- and H2-receptor agonists in guinea-pig right atria.

Authors:  G J Molderings; H J Schümann
Journal:  Arch Int Pharmacodyn Ther       Date:  1989 Jan-Feb

5.  Transgenic mice with cardiac overexpression of alpha1B-adrenergic receptors. In vivo alpha1-adrenergic receptor-mediated regulation of beta-adrenergic signaling.

Authors:  S A Akhter; C A Milano; K F Shotwell; M C Cho; H A Rockman; R J Lefkowitz; W J Koch
Journal:  J Biol Chem       Date:  1997-08-22       Impact factor: 5.157

6.  Vanadate stimulates adenylate cyclase via the guanine nucleotide regulatory protein by a mechanism differing from that of fluoride.

Authors:  W Krawietz; R W Downs; A M Spiegel; G D Aurbach
Journal:  Biochem Pharmacol       Date:  1982-03-01       Impact factor: 5.858

7.  alpha-Adrenergic inhibition of the beta-adrenoceptor-dependent chloride current in guinea-pig ventricular myocytes.

Authors:  I Iyadomi; K Hirahara; T Ehara
Journal:  J Physiol       Date:  1995-11-15       Impact factor: 5.182

Review 8.  Subtypes of alpha 1- and alpha 2-adrenergic receptors.

Authors:  D B Bylund
Journal:  FASEB J       Date:  1992-02-01       Impact factor: 5.191

9.  Cardiac-specific overexpression of alpha1BAR regulates betaAR activity via molecular crosstalk.

Authors:  I Lemire; B G Allen; H Rindt; T E Hebert
Journal:  J Mol Cell Cardiol       Date:  1998-09       Impact factor: 5.000

10.  The tyrosine kinase inhibitor, genistein, prevents alpha-adrenergic-induced cardiac muscle cell hypertrophy by inhibiting activation of the Ras-MAP kinase signaling pathway.

Authors:  J Thorburn; A Thorburn
Journal:  Biochem Biophys Res Commun       Date:  1994-08-15       Impact factor: 3.575

View more
  6 in total

1.  Redox modulation of basal and beta-adrenergically stimulated cardiac L-type Ca(2+) channel activity by phenylarsine oxide.

Authors:  Carl Sims; Robert D Harvey
Journal:  Br J Pharmacol       Date:  2004-06-01       Impact factor: 8.739

2.  Differential action of a protein tyrosine kinase inhibitor, genistein, on the positive inotropic effect of endothelin-1 and norepinephrine in canine ventricular myocardium.

Authors:  Li Chu; Jian-Xin Zhang; Ikuo Norota; Masao Endoh
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

3.  Role of tyrosine kinase activity in alpha-adrenergic inhibition of the beta-adrenergically regulated L-type Ca(2+) current in guinea-pig ventricular myocytes.

Authors:  A E Belevych; A Nulton-Persson; C Sims; R D Harvey
Journal:  J Physiol       Date:  2001-12-15       Impact factor: 5.182

Review 4.  Caveolae create local signalling domains through their distinct protein content, lipid profile and morphology.

Authors:  Robert D Harvey; Sarah C Calaghan
Journal:  J Mol Cell Cardiol       Date:  2011-07-19       Impact factor: 5.000

Review 5.  Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance.

Authors:  Timothy D O'Connell; Brian C Jensen; Anthony J Baker; Paul C Simpson
Journal:  Pharmacol Rev       Date:  2013-12-24       Impact factor: 25.468

6.  Pharmacological evidence for altered src kinase regulation of I (Ca,L) in patients with chronic atrial fibrillation.

Authors:  Maura Greiser; Christian R Halaszovich; Dirk Frechen; Peter Boknik; Ursula Ravens; Dobromir Dobrev; Andreas Lückhoff; Ulrich Schotten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-06-26       Impact factor: 3.195

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.